Carl Hansen, AbCellera CEO (AbCellera)

Lil­ly's Covid-19 part­ner Ab­Cellera is tak­ing a new an­ti­body in­to the clin­ic in the hopes it can tack­le all vari­ants

As the virus be­hind the Covid-19 pan­dem­ic con­tin­ues to mu­tate in­to sev­er­al vari­ants of con­cern, the com­pa­ny be­hind Eli Lil­ly’s bam­lanivimab an­ti­body treat­ment is look­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.